Skip to main content
Log in

Different binding and degradation of proinsulin, insulin and insulin-like growth factor-1 (IGF-1) in cultured renal proximal tubular cells

Implications for the prolonged serum half-life of proinsulin

  • Original
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Recent studies have reported that elevated proinsulin levels are indicative of an increased cardiovascular risk. Renal proximal tubular cells represent a major site for the metabolism of insulin-like hormones after glomerular filtration into the tubular lumen. To determine the binding and degradation of proinsulin in comparison with insulin and insulin-like growth factor-1 (IGF-1), we have used a rabbit proximal tubular cell line (PT-1). As confirmed by electron microscopy, PT-1 cells exhibit bipolar differentiation, demonstrating apical microvilli and invaginations of the basolateral membrane. To allow selective incubation of both compartments, cells were grown on filter membranes. Performing equilibrium binding assays with125I-labelled hormones, severalfold higher binding was found at the apical than at the basolateral cell membrane, with the capacity range IGF-1>insulin>proinsulin. Half-maximal displacement of125I-labelled insulin and IGF-1 was observed at 0.6 and 2 nM, respectively, while crossover binding to the alternate receptor occurred with a 10- to 100-fold lower affinity. Half-maximal displacement of125I-proinsulin binding was obtained at approx. 8 nM proinsulin and insulin, whereas IGF-1 was 10-fold less potent. The relative degradation of specifically bound tracer was lowest for proinsulin (apical: 10%, basolateral: 13%). IGF-1 was degraded by 20% at the apical cell membrane, and up to 78% at the basolateral membrane. In contrast, almost the total amount of insulin bound was degraded at both membrane sites (apical: 99%, basolateral: 83%). These results suggest separate insulin and IGF-1 receptors, while proinsulin binds with high affinity to a third insulin-like receptor on the apical membrane of PT-1 cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Rinderknecht E, Humbel RE, The amino acid sequence of human insulin-like growth factor I and its structural homology to proinsulin. J Biol Chem 253:2769–2776, 1978

    Google Scholar 

  2. De Meyts P, The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 37 [Suppl 2]:135–148, 1994

    Google Scholar 

  3. Podlecki DA, Frank BH, Olefsky JM, In vitro characterization of biosynthetic human proinsulin. Diabetes 33:111–118, 1984

    Google Scholar 

  4. Rausch UW, Fussgaenger RD, Heinze E, Qualitative dissimilarities of insulin and proinsulin binding and action in vitro at IM-9 lymphocytes. Horm Metab Res Suppl 1/88:88–92, 1988

    Google Scholar 

  5. Nissley SP, Rechler MM, Moses AC, Short PA, Podskalny JM, Proinsulin binds to a growth peptide receptor and stimulates DNA synthesis in chick embryo fibroblasts. Endocrinology 101:708–716, 1976

    Google Scholar 

  6. Schneider DJ, Nordt TK, Sobel BE, Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 41:890–895, 1992

    Google Scholar 

  7. Nordt TK, Schneider DJ, Sobel BE, Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 89:321–330, 1994

    Google Scholar 

  8. Duckworth WC, Kitabchi AE, Direct measurement of plasma proinsulin in normal and diabetic subjects. Am J Med 53:418–427, 1972

    Google Scholar 

  9. Cohen RM, Nathan DM, Clements RS, Hyperproinsulinemia in type II diabetes. Diabetes Care 15:723–724, 1992

    Google Scholar 

  10. Revers RR, Henry R, Schmeiser L, Schmeiser O, Koltermann R, Cohen R, Bergenstal R, Polonsky KS, Jaspan JB, Rubenstein AH, Frank B, Galloway J, Olefsky JM, The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes 33:762–770, 1984

    Google Scholar 

  11. Hammerman MR, Interaction of insulin with the renal proximal tubular cell. Am J Physiol 249: F1-F11, 1985

    Google Scholar 

  12. Talor Z, Emmanouel DS, Katz AI, Insulin binding and degradation by luminal and basolateral tubular membranes from rat kidney. J Clin Invest 69:1136–1146, 1982

    Google Scholar 

  13. Yagil C, Frank BH, Rabkin R, Internalization and catabolism of insulin by an established renal cell line. Am J Physiol 254: C822-C828, 1988

    Google Scholar 

  14. Frank BH, Beckage MJ, Willey KA, High-performance liquid chromatographic preparation of single-site carrier-free pancreatic polypeptide hormone radiotracers. J Chromatography 266:239–248, 1983

    Google Scholar 

  15. Cheng YC, Prusoff WH, Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108, 1973

    Google Scholar 

  16. Hintz RL, Thorsson AV, Enberg G, Hall K, IGF-II binding on human lymphoid cells: Demonstration of a common high affinity receptor for insulin-like peptides. Biochem Biophys Res Commun 118:774–782, 1984

    Google Scholar 

  17. Jonas HA, Cox AJ, Insulin receptor subtypes in a human lymphoid-derived cell line (IM-9): Differential regulation by insulin, dexamethasone and monensin. J Recept Res 11:813–829, 1991

    Google Scholar 

  18. Blazer-Yost BL, Watanabe M, Haverty TP, Ziyadeh FN, Role of insulin and IGF1 receptors in proliferation of cultured renal proximal tubule cells. Biochim Biophys Acta 1133:329–335, 1992

    Google Scholar 

  19. Fussgaenger RD, Ditschuneit HH, Martini H, Wiebauer-De Lenardis H, Etzrodt H, Thun CH, Ditschuneit H, Pfeiffer EF, Enzmann F, Potency of biosynthetic human insulin determined in vitro. Diabetes Care 4:228–234, 1981

    Google Scholar 

  20. Jehle PM, Lutz MP, Fussgaenger RD, High affinity binding sites for proinsulin in human IM-9 lymphoblasts. Diabetologia 39:421–432, 1996

    Google Scholar 

  21. Rubenstein AH, Pottenger LA, Mako M, Getz GS, Steiner DF, The metabolism of proinsulin and insulin by the liver. J Clin Invest 51:912–921, 1973

    Google Scholar 

  22. Kitabchi AE, Proinsulin and C-peptide: a review. Metabolism 26:547–587, 1977

    Google Scholar 

  23. Zapf A, Hsu D, Olefsky JM, Comparison of the intracellular itineraries of insulin-like growth factor-I and insulin and their receptors in rat-1 fibroblasts. Endocrinology 134:2445–2452, 1994

    Google Scholar 

  24. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, Schneider AE, Hales CN, Yudkin JS, The relationships of concentrations of insulin, intact proinsulin, and 32–33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 33:532–537, 1990

    Google Scholar 

  25. Haffner SM, Mykkänen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR, Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects. Diabetes 42:1297–1302, 1993

    Google Scholar 

  26. Reaven GM, Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 44:121–131, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jehle, P.M., Fußgänger, R.D., Stracke, S. et al. Different binding and degradation of proinsulin, insulin and insulin-like growth factor-1 (IGF-1) in cultured renal proximal tubular cells. Acta Diabetol 33, 159–165 (1996). https://doi.org/10.1007/BF00569428

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00569428

Key words

Navigation